one of my favorites...even in this mkt...this today:
(PR NEWSWIRE) Hadron Subsidiary Awarded $2.6 Million Anthrax Research Contrac
Hadron Subsidiary Awarded $2.6 Million Anthrax Research Contract By the United
States Army Medical Research and Materiel Command
ALEXANDRIA, Va., March 22 /PRNewswire/ --
Hadron, Inc. (OTC Bulletin Board: HDRN) today announced that its Advanced
Biosystems, Inc. subsidiary has been awarded a $2.6 million, one-year contract
by the U.S. Army Medical Research and Materiel Command to study and develop
new medical defenses for anthrax.
This contract is a major step in Advanced Biosystems' multi-phase program
to develop defenses against, and treatments for, specific biological agents
that may be used in warfare or terrorist attacks. This research will develop
innovative medical approaches to treating anthrax, including methods of
enhancing antibiotic therapies, modulating the host immune response, and new
methods to battle anthrax sepsis and septic shock.
Advanced Biosystems' President, Dr. Ken Alibek, said, "The research
program funded by this contract will explore promising alternatives to the
present medical defense approaches to anthrax. These new alternatives are
based on a new view of anthrax etiology and pathogenesis." Sterling E.
Phillips, Jr., Hadron's President and Chief Executive Officer, added, "We are
pleased that Hadron has been chosen to perform this research, in an area so
important to our national security. Contracts such as this are key to the
aggressive growth potential we see in developing novel treatment and
prophylactic approaches for many other biological threat agents that could be
used in biological warfare and terrorism."
Hadron specializes in developing innovative intelligence and biodefense
solutions in support of our Nation's national security. Hadron focuses on
developing innovative technical solutions for the intelligence community,
analyzing and supporting defense systems and developing medical defenses and
treatments for toxic agents used in biological warfare and terrorism. The
Company's stock trades on the OTC Electronic Bulletin Board under the symbol
HDRN. Hadron can be found on the Internet at www.hadron.com . Hadron
investor relations can be contacted at (703) 329-9400 or via email at
agordon@hadron.com .
Except for the historical information contained herein, this press release
contains forward-looking statements within the meaning of Section 21E of the
Securities and Exchange Act of 1934, as amended, that involve a number of
risks and uncertainties. These forward-looking statements may be identified
by reference to a future period by use of forward-looking terminology such as
"anticipate," "expect," "could," "intend," "may" and other words of similar
nature. There are certain important factors and risks that could cause
results to differ materially from those anticipated by the statements
contained herein. Such factors and risks include business conditions and
growth in the information services, engineering services, software development
and government contracting arenas and in the economy in general. Competitive
factors include the pressures toward consolidation of small government
contracts into larger contracts awarded to major, multi-national corporations;
and the Company's ability to continue to recruit and retain highly skilled
technical, managerial and sales/marketing personnel. Other risks may be
detailed from time to time in the Company's filings with the Securities and
Exchange Commission. Hadron undertakes no obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.
SOURCE Hadron, Inc.
-0- 03/22/2001
/CONTACT: Amber Gordon or Sterling Phillips, both of Hadron,
703-329-9400/
/Web site: hadron.com
(HDRN)
CO: Hadron, Inc.; U.S. Army Medical Research and Materiel Command; Advanced
Biosystems, Inc.
ST: Virginia
IN: CPR ARO BIO
SU: CON
*** end of story *** |
